Last week, Biogen announced it would price Eloctate at $1.98 per unit, a cost ISI Group analyst Mark Schoenebaum wrote in a note to investors was "in-line" with Baxter's ($BAX) Advate at about $550,000 to $600,000 per year. And taking into account Eloctate's less frequent infusion schedule--a dose is needed once every three to 5 days, as opposed to the standard twice- or thrice-weekly regimen--similar costs may lure patients toward Biogen's med.
http://www.fiercepharmamarketing.com/story/biogen-prices-new-long-acting-hemophilia-med-eye-patient-switching/2014-07-09
No comments:
Post a Comment